Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
110.62
+1.57 (1.44%)
At close: Mar 3, 2025, 4:00 PM
111.69
+1.07 (0.97%)
Pre-market: Mar 4, 2025, 6:16 AM EST
Novartis AG Revenue
In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth. Novartis AG had revenue of $13.56B in the quarter ending December 31, 2024, with 15.13% growth.
Revenue (ttm)
$51.72B
Revenue Growth
+10.85%
P/S Ratio
4.21
Revenue / Employee
$681,602
Employees
75,883
Market Cap
217.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
NVS News
- 3 days ago - Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) - PRNewsWire
- 3 days ago - Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G) - GlobeNewsWire
- 4 days ago - Why Novartis Remains A 'Buy' After Beating Expectations Again - Seeking Alpha
- 6 days ago - Syngenta acquires genetic repository from Novartis to boost biologic crop protection - Reuters
- 6 days ago - Sandoz family foundation offers $3 billion worth of Novartis shares - Reuters
- 16 days ago - Novartis: Strong Execution With A P/E Discount - Seeking Alpha
- 17 days ago - Novartis: Just What The Doctor Ordered - Seeking Alpha
- 21 days ago - Novartis agrees to acquire Anthos for up to $3.1 bln - Reuters